ASBM Presents at WHO’s 74th INN Consultation

April 10, 2022

On April 5th, ASBM participated in the World Health Organization’s 74th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the eighteenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. The proceedings at the […]

Read More


ASBM Leads Sessions at Festival of Biologics USA 2022

March 20, 2022

From March 9-11, ASBM participated in the Festival of Biologics USA 2022, held in San Diego, California. Several ASBM representatives presented on a variety of topics, and participated in several discussion panels at the three-day conference. On March 9th, ASBM Advisory Board Chair Philip Schneider gave a plenary presentation on the current biosimilars landscape, highlighting factors which […]

Read More


Bill Would Eliminate Requirement For Biosimilars to Have Equal Strength as Originator Biologics

March 15, 2022

On March 9th, a bill was introduced in the U.S. House of Representatives that would eliminate the requirement for a biosimilar to have the same strength as the originator product upon which it is based. H.R. 7047, the “Lowering Costs by Improving Biosimilar Uptake Act”, would amend title III of the Public Health Service, permitting the Secretary of […]

Read More


VA Study: Patients Switched to Biosimilar Infliximab More Likely to Stop Treatment

March 8, 2022

On February 18th, a study was published in the journal Current Medical Research and Opinion, which examined US Veterans Healthcare Administration (VHA) patients who were switched from innovator infliximab to the VHA-preferred biosimilar. The study found that those who were switched from the reference product to the biosimilar were almost 3 times more likely to stop treatment and 5 times more likely […]

Read More


ASBM Video Shares US Physician Perspectives on Non-Medical Switching

February 28, 2022

ASBM has released our latest video, “Non-Medical Switching”, featuring ASBM Chairman Ralph McKibbin, MD. In the video, Dr. McKibbin shares new data from ASBM’s recent survey of 401 U.S. prescribers of biologics, as well as his own observations on the controversial practice. Among the survey findings: 69% of US physicians surveyed consider it “very important or critical” […]

Read More


ASBM Urges Reform on Copay Accumulator Adjustments

February 10, 2022

On January 27th, ASBM joined other patient advocacy organizations and physician groups in submitting a coalition letter to the U.S. Department of Health and Human Services (HHS), urging the Department to prohibit the practice of copay accumulator adjustment policies. The coalition letter was submitted as part of the comment period on the HHS Notice of Benefit and Payment Parameters […]

Read More


ASBM to Participate in Festival of Biologics USA 2022

February 3, 2022

From March 9-11, ASBM will participate in the Festival of Biologics USA 2022, held in San Diego, California. Two ASBM representatives will be presenting on a variety of topics, and moderating several discussion panels at the three-day conference. On March 9th, ASBM Advisory Board Chair Philip Schneider will give a Plenary Presentation on the current biosimilars landscape, […]

Read More


ASBM’s Madelaine Feldman Discusses Role of PBMs in Increasing Drug Prices

February 3, 2022

On January 25th, ASBM’s Immediate Past Chair Madelaine Feldman, MD FACR participated in a webinar entitiled “What’s the Hold-Up? Overcoming Barriers to the Use of Biosimilars,” hosted by The Center for Biosimilars. At the forum, Dr. Feldman discussed the role of payers like insurance companies and pharmacy benefit managers (PBMs) in contributing to higher drug […]

Read More


ASBM Presents at 16th Biosimilars Congregation

January 30, 2022

On December 9th, ASBM participated in the 16th Biosimilar Congregation, which focused on the Indian biosimilars market. By 2030, India is expected to become the sixth-largest market for pharmaceuticals, and has already firmly established itself in the global biopharmaceutical market. Many Indian pharmaceutical companies are preparing to step into the global biosimilars market. ASBM was […]

Read More


ASBM Letter to Congress: Paying Physicians to Prescribe Government-Preferred Biosimilars Undermines Patient-Physician Relationship

January 30, 2022

On December 2nd, ASBM sent a letter to House leaders reiterating our opposition to a proposal that would undermine the patient-physician relationship and distort the making of treatment decisions. The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their […]

Read More